Claims for Patent: 12,213,988

Summary for Patent: 12,213,988

Title:	Methods of treating chronic kidney disease with dapagliflozin
Abstract:	The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.
Inventor(s):	Anna Maria LANGKILDE
Assignee:	AstraZeneca AB
Application Number:	US17/347,230
Patent Claims:	1. A method for treating a patient with chronic kidney disease at risk of progression, the method comprising: administering dapagliflozin once daily to the patient at a dose and duration sufficient to reduce the patient's risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death, and hospitalization for heart failure; wherein the patient does not have type II diabetes; and wherein the duration is at least four months. 2. The method of claim 1, wherein the sustained decline in eGFR is ≥50%. 3. The method of claim 1, wherein the end-stage kidney disease (ESKD) comprises sustained eGFR <15 mL/min/1.73 m2, initiation of chronic dialysis treatment and/or renal transplant. 4. The method of claim 1, wherein prior to the administration, the patient had (i) an eGFR ≥25 and ≤75 mL/min/1.73 m2; and/or (ii) a urine albumin creatinine ratio (UACR) ≥200 and ≤5000 mg/g. 5. The method of claim 1, wherein (i) prior to the administration, the patient was receiving an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB); and/or (ii) during the administration, the patient is also administered an ACEi or an ARB. 6. The method of claim 5, wherein the angiotensin-converting enzyme inhibitor (ACEi) is chosen from captopril, enalapril, and lisinopril. 7. The method of claim 5, wherein the angiotensin receptor blocker (ARB) is chosen from valsartan, losartan, and irbesartan. 8. A method for treating a patient with chronic kidney disease at risk of progression, the method comprising: administering dapagliflozin once daily to the patient at a dose and duration sufficient to reduce a risk of an incidence of a composite endpoint; wherein the patient does not have type II diabetes; wherein the composite endpoint is ˜50% sustained decline in estimated glomerular filtration rate (eGFR), progression to end-stage kidney disease (ESKD), and CV or renal death; and wherein the duration is at least four months. 9. The method of claim 8, wherein the end-stage kidney disease (ESKD) comprises sustained eGFR <15 mL/min/1.73 m2, initiation of chronic dialysis treatment and/or renal transplant. 10. The method of claim 8, wherein prior to the administration, the patient had (i) an eGFR ≥25 and ≤75 mL/min/1.73 m2; and/or (ii) a urine albumin creatinine ratio (UACR) ≥200 and ≤5000 mg/g. 11. The method of claim 8, wherein (i) prior to the administration, the patient was receiving an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB); and/or (ii) during the administration, the patient is also administered an ACEi or an ARB. 12. The method of claim 11, wherein the angiotensin-converting enzyme inhibitor (ACEi) is chosen from captopril, enalapril, and lisinopril. 13. The method of claim 11, wherein the angiotensin receptor blocker (ARB) is chosen from valsartan, losartan, and irbesartan. 14. The method of claim 8, wherein the method satisfies at least one of the following conditions: a) the method results in a hazard ratio for time to first event in the composite endpoint that is less than one relative to an administration regimen where the patient receives no dapagliflozin; b) the method results in a hazard ratio for time to first event in the composite endpoint that is statistically nominally less than one relative to an administration regimen where the patient receives no dapagliflozin; c) the method results in a hazard ratio for time to first event in the composite endpoint of approximately 0.61 relative to an administration regimen where the patient receives no dapagliflozin; d) the method results in a 95% confidence interval for the hazard ratio for time to first event in the composite endpoint of approximately 0.51 to 0.72 relative to an administration regimen where the patient receives no dapagliflozin; e) the method numerically reduces the absolute risk of the composite endpoint relative to an administration regimen where the patient receives no dapagliflozin; f) the method results in a nominally significant risk reduction of the composite endpoint relative to an administration regimen where the patient receives no dapagliflozin; g) the method results in a numerical reduction in the composite endpoint relative to an administration regimen where the patient receives no dapagliflozin; h) the method results in a hazard ratio for time to first event in a composite endpoint of CV death and hospitalization for heart failure of approximately 0.71 relative to an administration regimen where the patient receives no dapagliflozin; and/or i) the method results in a hazard ratio for time to death from all causes of approximately 0.69 relative to an administration regimen where the patient receives no dapagliflozin. 15. The method of claim 1, wherein the method further comprises administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of AZD9977 or a pharmaceutically acceptable salt thereof. 16. The method of claim 15, wherein the patient is at high risk for hyperkalemia. 17. The method of claim 15, wherein the therapeutically effective amount of AZD9977 or a pharmaceutically acceptable salt thereof is 15-150 mg daily. 18. The method of claim 15, wherein the therapeutically effective amount of dapagliflozin is 10 mg orally once per day. 19. The method of claim 8, wherein the method further comprises administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of AZD9977 or a pharmaceutically acceptable salt thereof. 20. The method of claim 19, wherein the patient is at high risk for hyperkalemia. 21. The method of claim 19, wherein the therapeutically effective amount of AZD9977 or a pharmaceutically acceptable salt thereof is 15-150 mg daily. 22. The method of claim 19, wherein the amount of dapagliflozin is 10 mg orally once per day. 23. The method of claim 1, wherein the patient is not on chronic dialysis. 24. The method of claim 8, wherein the patient is not on chronic dialysis.